A recurrent activating missense mutation in waldenstrom macroglobulinemia affects the DNA binding of the ETS transcription factor SPI1 and enhances proliferation
Published version of a preprint
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues and contribute to cellular processes, including proliferation and transformation. ETS genes are targeted through genomic rearrangements in oncogenesis. The PU.1/SPI1 gene is inactivated by point mutations in human myeloid malignancies. We identified a recurrent somatic mutation (Q226E) in PU.1/SPI1 in Waldenström macroglobulinemia, a B-cell lymphoproliferative disorder. It affects the DNA-binding affinity of the protein and allows the mutant protein to more frequently bind and activate promoter regions with respect to wild-type protein. Mutant SPI1 binding at promoters activates gene sets typically promoted by other ETS factors, resulting in enhanced proliferation and decreased terminal B-cell differentiation in model cell lines and primary samples. In summary, we describe oncogenic subversion of transcription factor function through subtle alteration of DNA binding leading to cellular proliferation and differentiation arrest. Significance: The demonstration that a somatic point mutation tips the balance of genome-binding pattern provides a mechanistic paradigm for how missense mutations in transcription factor genes may be oncogenic in human tumors. This article is highlighted in the In This Issue feature, p. 681
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the erythroid lineage, in which SPI1 exerts an oncogenic function by blocking differentiation.”
From HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia (2022) · cites this paper as [19]
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Genetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
The ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Mutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Self-citationOwen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., San Miguel, J. F., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 924
Chromatin-state discovery and genome annotation with ChromHMM
Ernst, J., & Kellis, M. (2017) · Nature Protocols · doi:10.1038/nprot.2017.124 · Cited by 910
Cited by
From multi-omics approaches to personalized medicine in myocardial infarction
Zhan, C., Tang, T., Wu, E., Zhang, Y., He, M., Wu, R., Bi, C., Wang, J., Zhang, Y., & Shen, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1250340 · Cited by 72
Lazarian, G., Yin, S., ten Hacken, E., Sewastianik, T., Uduman, M., Font‐Tello, A., Gohil, S. H., Li, S., Kim, E., Joyal, H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.003 · Cited by 57
“Moreover, the same hotspot mutation has been previously identified in diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma and Waldenström’s macroglobulinemia, suggesting its critical role in the malignant transformation of B cells (Bea et al., 2013; Morin et al., 2011; Roos-Weil et al., 2019).”
BackgroundKrzisch, D., Guedes, N. R., Boccon‐Gibod, C., Baron, M., Bravetti, C., Davi, F., Armand, M., Smagghe, L., Caron, J., Bernard, O., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26339 · Cited by 49
“Both SPI1 and IKZF3 (3%) mutations were respectively hotspot Q226E and L162R.(13,34) The median number of cytogenetic abnormalities per sample was two (0–22).”
BackgroundResultSelf-citationYao, J., Duan, L., Huang, X., Liu, J., Fan, X., Xiao, Z., Yan, R., Liu, H., An, G., Hu, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769727 · Cited by 47
“Alterations in SPI1 lead to oncogenic subversion by cellular proliferation and differentiation arrest in Waldenström macroglobulinemia (55).”
BackgroundKRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
Vendramini, E., Bomben, R., Pozzo, F., Bittolo, T., Tissino, E., Gattei, V., & Zucchetto, A. (2022) · Cancers · doi:10.3390/cancers14030666 · Cited by 41
Zhang, D., Qian, C., Wei, H., & Qian, X. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.599475 · Cited by 29
“Alterations in SPI1 lead to cellular proliferation and differentiation arrest, resulting in oncogenic subversion (Roos-Weil et al., 2019).”
BackgroundHan, R., Yuan, T., Yang, Z. H., Zhang, Q., Wang, W., Lin, L., Zhu, M.-Q., & Gao, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105345 · Cited by 32
Gregoricchio, S., Polit, L., Esposito, M., Berthelet, J., Delestré, L., Evanno, E., Diop, M., Gallais, I., Aleth, H., Poplineau, M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac613 · Cited by 27
Self-citationDella-Valle, V., Roos‐Weil, D., Scourzic, L., Mouly, E., Aid, Z., Darwiche, W., Lécluse, Y., Damm, F., Mémet, S., Mercher, T., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0305-6 · Cited by 27
Self-citationTranscriptional reprogramming by mutated IRF4 in lymphoma
Schleußner, N., Cauchy, P., Franke, V., Giefing, M., Fornés, O., Vankadari, N., Assi, S. A., Costanza, M., Weniger, M. A., Akalin, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41954-8 · Cited by 27
Self-citationThillo, Q. V., Bie, J. D., Seneviratne, J. A., Demeyer, S., Omari, S. A., Balachandran, A., Zhai, V., Tam, W. L., Sweron, B., Geerdens, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24442-9 · Cited by 21
DNA selection by the master transcription factor PU.1
Terrell, J. R., Taylor, S. J., Schneider, A. L., Lu, Y., Vernon, T. N., Xhani, S., Gumpper, R. H., Luo, M., Wilson, W. D., Steidl, U. G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112671 · Cited by 25
Roos‐Weil, D., Giacopelli, B., Armand, M., Della-Valle, V., Ghamlouch, H., Decaudin, C., Metzner, M., Lu, J., Garff‐Tavernier, M. L., Leblond, V., et al. (2020) · Blood · doi:10.1182/blood.2020005081 · Cited by 17
Self-citationLiu, Z., & Huang, S. (2022) · PubMed Central · Cited by 14
A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes
Gagler, D. C., Ghamlouch, H., Zhang, D., Blaney, P., Tenenbaum, A., Langton, J., Armand, M., Eeckhoutte, A., Joudat, A., Degaud, M., et al. (2025) · Blood · doi:10.1182/blood.2024028164 · Cited by 14
Self-citationAIOLOS-Associated Inborn Errors of Immunity
Yamashita, M., & Morio, T. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01730-9 · Cited by 12
“Additionally, somatic mutations in IKZF3 have been observed in Waldenström macroglobulinemia [31] and non-Hodgkin’s lymphoma [32], while the somatic L162R missense mutation has been commonly identified in CLL [33].”
BackgroundOne hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them
Knox, A. V. C., Cominsky, L. Y., Sun, D., Cabrera, E. C., Nolan, B. E., Ofray, E., Benetti, E., Visconti, C., Barzaghi, F., Rosenzweig, S. D., et al. (2025) · Blood · doi:10.1182/blood.2024026683 · Cited by 11
Drandi, D., Decruyenaere, P., Ferrante, M., Offner, F. C., Vandesompele, J., & Ferrero, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040969 · Cited by 9
Song, Q., Wang, Y., & Liu, S. (2024) · Cancer Innovation · doi:10.1002/cai2.138 · Cited by 10
Zerella, J. R., Homan, C. C., Arts, P., Brown, A. L., Scott, H. S., & Hahn, C. N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1183318 · Cited by 6
Pawlikowska, P., Delestré, L., Gregoricchio, S., Oppezzo, A., Esposito, M., Diop, M. K., Rosselli, F., & Guillouf, C. (2023) · Oncogene · doi:10.1038/s41388-023-02800-9 · Cited by 6
Self-citationWaldenström’s macroglobulinemia: The LYSA pragmatic guidelines
Roos‐Weil, D., Tomowiak, C., Poulain, S., Nguyen‐Khac, F., Bouclet, F., Armand, M., Aurran, T., Durot, É., Ghez, D., Hivert, B., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116120 · Cited by 5
Self-citationVernon, T. N., Terrell, J. R., Albrecht, A. V., Germann, M. W., Wilson, W. D., & Poon, G. M. K. (2023) · Structure · doi:10.1016/j.str.2023.11.003 · Cited by 4
Waldenstrom’s Macroglobulinemia
Buske, C., & Leblond, V. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-55989-2_10 · Cited by 4
Self-citationWang, Q., Li, T., Fang, C., & Zhang, B. (2021) · Ibrain · doi:10.1002/ibra.12006 · Cited by 4
“The Spi1 gene encodes an ETS‐domain transcription factor that activates gene expression during myeloid and B‐lymphoid cell development.(35) Fcer1g, a high‐affinity IgE receptor, is a key molecule involved in allergic reactions.”
BackgroundTherapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC
Xue, W., Wu, Z., Li, J., Jin, P., Zhu, Y., Li, Z., Wang, Z., Li, Z., & Fei, X. (2025) · Communications Biology · doi:10.1038/s42003-025-08900-4 · Cited by 3
“However, research has also identi fi ed transcriptional repression effects associated with abnormally high SPI1 expression, which can act as an oncogenic factor 17,18 .”
Ma, J., Zhang, Y., Jiao, M., Feng, C., Ding, J., Cui, Y., Long, Y., & Xing, Z. (2026) · Industrial Crops and Products · doi:10.1016/j.indcrop.2026.123005 · Cited by 3
Lefebvre, C., Véronèse, L., Nadal, N., Gaillard, J.-B., Penther, D., Daudignon, A., Chauzeix, J., Nguyen‐Khac, F., & Chapiro, É. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103425 · Cited by 3
Self-citationClinical Implications of Genomic Profile in Waldenström Macroglobulinemia
Moreno, D. F., & de Larrea, C. F. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.04.002 · Cited by 2
Liu, S., Liu, X., Yusuf, C. F. B., Kofides, A., Soroko, K. M., Peñailillo, J., Canning, A. G., Cao, Y., Yang, G., Xu, L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20072 · Cited by 1
“While AKAP , HDAC5 and RUNX3 mutations have not been reported in WM, the finding of the SPI1 Q227E was of great interest since this mutation was found in 6% of a discovery and validation cohort in studies by Roos-Weil et al. 36 The expression of SPI1 Q227E (identified as SPI1 Q226E in their studies due to different is…”
A new type of transcriptional reprogramming by an IRF4 mutation in lymphomaPreprint
Schleußner, N., Cauchy, P., Franke, V., Giefing, M., Fornés, O., Vankadari, N., Assi, S. A., Costanza, M., Weniger, M. A., Akalin, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.29.522203 · Cited by 1
Self-citationBuske, C., & Leblond, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-22881-0_10
Self-citationDuraisamy, B., & Pramanik, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694912
Decaudin, C. (2020) · theses.fr (ABES) · doi:10.70675/e84f591cz6a69z4d60z9d03z6267895b1a9e
Self-citationOppezzo, A. (2021) · theses.fr (ABES) · doi:10.70675/53736911zeb54z418czb336z493f788bd19f
Ramani, M., Nguyen, N., Solis, J., Tenen, D. G., & Trinh, B. Q. (2026) · Biology · doi:10.3390/biology15181657
“Importantly, mutations affecting https://doi.org/10.3390/biology15181657 ETS-domain residues can alter DNA-binding affinity or specificity and have been linked to malignant transformation, particularly in B-cell neoplasms and hematologic cancers [25,30].”
Influential
Metadata
- Authors
- Roos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., Haddad, R., Mylonas, E., Damm, F., Pflumio, F., Stoilova, B., Metzner, M., Elemento, O., Dessen, P., Camara-Clayette, V., Cosset, F.-L., Verhoeyen, E., Leblond, V., Ribrag, V., Cornillet-Lefebvre, P., Rameau, P., Azar, N., Charlotte, F., Morel, P., Charbonnier, J.-B., Vyas, P., Mercher, T., Aoufouchi, S., Droin, N., Guillouf, C., Nguyen-Khac, F., & Bernard, O. A.
- Affiliations
- 1INSERM U1170, Gustave Roussy, Villejuif, France.
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- 10Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- 9Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA) DSV-IRCM-SCSR-LSHL, Université Paris Diderot Sorbonne Paris Cité, Fontenay-aux-Roses, France.
- University of Oxford (GB)
- Cornell University (US)
- Lyon 1 Université (FR)
- Sorbonne Université (FR)
- 16Laboratoire d'hématologie, Pôle de biologie, CHU de Reims-Hôpital Robert Debré, Avenuedu Général Koenig, Reims, France.
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- 2Gustave Roussy, Villejuif, France.
- 5Sorbonne Université, Hôpital Pitié-Salpêtrière, APHP, Paris, France.
- Corresponding author
- Bernard, Olivier A.
- ORCID
- Roos-Weil, Damien
- Armand, Marine
- Della-Valle, Véronique
- Diop, M'boyba K.
- Ghamlouch, Hussein
- Ropars, Virginie
- Hérate, Cécile
- Haddad, Rima
- Mylonas, Elena
- Stoilova, Bilyana
- Metzner, Marlen
- Elemento, Olivier
- Dessen, Philippe
- Cosset, François-Loïc
- Verhoeyen, Els
- Leblond, Véronique
- Ribrag, Vincent
- Rameau, Philippe
- Charlotte, Frédéric
- Morel, Pierre
- Charbonnier, Jean-Baptiste
- Vyas, Paresh
- Mercher, Thomas
- Droin, Nathalie
- Guillouf, Christel
- Bernard, Olivier A.
- Venue
- Cancer Discovery
- Published
- 2019-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 796-811
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2940868784
- Cited by
- 38
- References
- 52
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- INSERM INCa (2013-PLBIO-09, 2016-PLBIO-068)
- JTC (2014-143)
- INCa (INCa-DGOS-INSERM_12551, INCA-DGOS-Inserm_12560)
- Association Laurette Fugain
- FRISBI (ANR-10-INBS-05)
- ARC (SFI20111203530)
- MRC (G1000729/94931, MR/L008963/1)
- Ile de France and Fondation de France (00067113)
- Fondation pour la Recherche Médicale
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Waldenström macroglobulinemia, ETS transcription factors, missense mutations, DNA binding affinity, transcriptional activation, B cell proliferation, B cell terminal differentiation, oncogenic transcription factor, somatic mutations, B-cell lymphoproliferative disorders
- MeSH terms
- Lenalidomide, Proto-Oncogene Protein Spi-1, Animals, Azepines, B-Lymphocytes, Base Sequence, Binding Sites, Cell Line, Gene Expression Regulation, Humans, Waldenstrom Macroglobulinemia, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Triazoles, Trans-Activators, Mutation, Missense, Cell Proliferation, Proto-Oncogene Proteins c-ets, Mice, Myeloid Differentiation Factor 88, Nucleotide Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.